Abbott selects AbbVie as new name for future research-based pharmaceutical company
21 March 2012 | By Abbott
AbbVie the new, independent research-based pharmaceutical company...
List view / Grid view
News
Interview with Susan Najjar, Marketing Director for Informatics at Thermo Fisher Scientific
Freddy White, European Pharmaceutical Review speaks to Marketing Director for Informatics at Thermo Fisher Scientific, Susan Najjar...
Update on FDA Advisory Committee vote on investigational medicine Ridaforolimus
20 March 2012 | By Merck
"Merck remains confident in the potential of the investigational agent ridaforolimus..."
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
20 March 2012 | By GlaxoSmithKline
“Treatment options for patients with advanced soft tissue sarcoma are limited..."
Abbott reinforces global vascular leadership with new data on innovative technologies at ACC 2012
20 March 2012 | By Abbott
Abbott announced the company's schedule of key presentations...
Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued
20 March 2012 | By AstraZeneca
Top-line results from the remaining Phase III studies - announced...
Merck and Safe Water Network launch Initiative
20 March 2012 | By Merck
Collaboration advances Merck's commitment to fighting disease to help the world be well...
Pradaxa® (dabigatran etexilate) receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
FDA approves first Boniva generics to treat or prevent osteoporosis
19 March 2012 | By FDA
The U.S. FDA approved the first generic versions of Boniva (ibandronate) tablets...
Merck and partners create the California Institute for Biomedical Research (Calibr)
19 March 2012 | By Merck
Calibr presents a new paradigm for academic-industry cooperation...
Abbott announces patient enrollment in two phase 3 studies of HUMIRA® (adalimumab)
Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS).
Results from phase 3 trial of TAK-085 for the treatment of Hyperlipidemia
19 March 2012 | By Takeda Pharmaceutical Company Limited
Results presented at 76th Annual Scientific Meeting of the Japanese Circulation Society in Fukuoka...
Pfizer pledges to strengthen lifelong health strategies for Asia-Pacific region
18 March 2012 | By Pfizer
Experts on ageing highlight importance of health as driver of economic growth...
Alcon gains exclusive ex-US rights for ocriplasmin
16 March 2012 | By Novartis
Potential first pharmacological treatment for symptomatic vitreomacular adhesion...
Sanofi to acquire Pluromed, Inc., expanding its presence in biosurgery
16 March 2012 | By Sanofi
Sanofi and Pluromed Inc. have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc...
